Cargando…

The role of taxanes in triple-negative breast cancer: literature review

Breast cancer (BC) is the most frequent tumor worldwide. Triple-negative BCs are characterized by the negative estrogen and progesterone receptors and negative HER2, and represent 15% of all BCs. In this review, data on the use of taxanes in triple-negative BCs are analyzed, concluding they are effe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mustacchi, Giorgio, De Laurentiis, Michelino
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4532347/ https://www.ncbi.nlm.nih.gov/pubmed/26273192 http://dx.doi.org/10.2147/DDDT.S86105

Ejemplares similares

The role of taxanes in triple-negative breast cancer: literature review [Corrigendum]
Publicado: (2015)

Biomarkers in Triple-Negative Breast Cancer: State-of-the-Art and Future Perspectives
por: Cocco, Stefania, et al.
Publicado: (2020)

Prognostic Value of Cancer Stem Cells Markers in Triple-Negative Breast Cancer
por: Collina, Francesca, et al.
Publicado: (2015)

Long-term complete response with third-line PARP inhibitor after immunotherapy in a patient with triple-negative breast cancer: a case report
por: Caputo, Roberta, et al.
Publicado: (2023)

Role of Taxanes in Triple-Negative Breast Cancer: A Study From Tertiary Cancer Center in South India
por: Lakshmaiah, K.C., et al.
Publicado: (2017)

Identified the novel resistant biomarkers for taxane-based therapy for triple-negative breast cancer
por: Chou, Ching-Wen, et al.
Publicado: (2021)

Evaluating anthracycline + taxane versus taxane-based chemotherapy in older women with node-negative triple-negative breast cancer: a SEER-Medicare study
por: Schreiber, Anna R., et al.
Publicado: (2021)

Triple-Negative Breast Cancer Comparison With Canine Mammary Tumors From Light Microscopy to Molecular Pathology
por: Amirkhani Namagerdi, Asadoor, et al.
Publicado: (2020)

Platinum and Taxane Based Adjuvant and Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: A Narrative Review
por: Tian, Hao, et al.
Publicado: (2021)

LncRNA HOTAIR up-regulation is strongly related with lymph nodes metastasis and LAR subtype of Triple Negative Breast Cancer
por: Collina, Francesca, et al.
Publicado: (2019)

Male Breast Cancer: From Molecular Genetics to Clinical Management
por: Pensabene, Matilde, et al.
Publicado: (2022)

Vinorelbine Plus Platinum in Patients with Metastatic Triple Negative Breast Cancer and Prior Anthracycline and Taxane Treatment
por: li, Meiying, et al.
Publicado: (2015)

Polo-like kinase 1 (Plk1) inhibition synergizes with taxanes in triple negative breast cancer
por: Giordano, Antonio, et al.
Publicado: (2019)

Neoadjuvant eribulin mesylate following anthracycline and taxane in triple negative breast cancer: Results from the HOPE study
por: Di Cosimo, Serena, et al.
Publicado: (2019)

NLRP3 as Putative Marker of Ipilimumab-Induced Cardiotoxicity in the Presence of Hyperglycemia in Estrogen-Responsive and Triple-Negative Breast Cancer Cells
por: Quagliariello, Vincenzo, et al.
Publicado: (2020)

How to Optimise Extended Adjuvant Treatment with Neratinib for Patients with Early HER2+ Breast Cancer
por: Untch, Michael, et al.
Publicado: (2021)

Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy
por: Darb-Esfahani, Silvia, et al.
Publicado: (2016)

Taxanes for the Treatment of Metastatic Breast Cancer
por: Gradishar, W.J.
Publicado: (2012)

Rare tumours of the breast
por: Esposito, Emanuela, et al.
Publicado: (2019)

Virtual Reality Rehabilitation Systems for Cancer Survivors: A Narrative Review of the Literature
por: Melillo, Antonio, et al.
Publicado: (2022)

Polymorphisms in AURKA and AURKB are associated with the survival of triple-negative breast cancer patients treated with taxane-based adjuvant chemotherapy
por: Liao, Yuqian, et al.
Publicado: (2018)

Resistance to Taxanes in Triple-Negative Breast Cancer Associates with the Dynamics of a CD49f+ Tumor-Initiating Population
por: Gómez-Miragaya, Jorge, et al.
Publicado: (2017)

Patterns and Predictors of First-Line Taxane Use in Patients with Metastatic Triple-Negative Breast Cancer in US Clinical Practice
por: O’Shaughnessy, Joyce, et al.
Publicado: (2021)

Gemcitabine and taxanes in metastatic breast cancer: a systematic review
por: Gudena, Vinay, et al.
Publicado: (2008)

Role of Immunotherapy in the Treatment of Triple-Negative Breast Cancer: A Literature Review
por: K Patel, Khushbu, et al.
Publicado: (2022)

Adipose microenvironment promotes triple negative breast cancer cell invasiveness and dissemination by producing CCL5
por: D’Esposito, Vittoria, et al.
Publicado: (2016)

Taxanes in the elderly patient with metastatic breast cancer
por: Yardley, Denise A
Publicado: (2015)

Programmed Death Ligand 1 (PD-L1) Tumor Expression Is Associated with a Better Prognosis and Diabetic Disease in Triple Negative Breast Cancer Patients
por: Botti, Gerardo, et al.
Publicado: (2017)

Insights into the Role of Estrogen Receptor β in Triple-Negative Breast Cancer
por: Sellitto, Assunta, et al.
Publicado: (2020)

Glucocorticoid Receptor Expression Predicts Good Outcome in response to Taxane-Free, Anthracycline-Based Therapy in Triple Negative Breast Cancer
por: Elkashif, Ahmed, et al.
Publicado: (2020)

Role of BET Inhibitors in Triple Negative Breast Cancers
por: Khandekar, Durga, et al.
Publicado: (2020)

The Roles of DNA Demethylases in Triple-Negative Breast Cancer
por: Panjarian, Shoghag, et al.
Publicado: (2021)

A systematic literature review on direct and indirect costs of triple-negative breast cancer
por: Rezaei, Sadeq, et al.
Publicado: (2023)

Long Non-Coding RNA HOTAIR in Breast Cancer Therapy
por: Cantile, Monica, et al.
Publicado: (2020)

Triple-negative breast cancer
por: Chacón, Reinaldo D, et al.
Publicado: (2010)

Characteristics of triple-negative breast cancer
por: de Ruijter, Tim C., et al.
Publicado: (2010)

Inhibition of autophagy by chloroquine prevents resistance to PI3K/AKT inhibitors and potentiates their antitumor effect in combination with paclitaxel in triple negative breast cancer models
por: Cocco, Stefania, et al.
Publicado: (2022)

The Role of Circulating Tumor Cells in the Prognosis of Metastatic Triple-Negative Breast Cancers: A Systematic Review of the Literature
por: Lisencu, Lorena Alexandra, et al.
Publicado: (2022)

Long Noncoding RNAs in Taxane Resistance of Breast Cancer
por: Chen, Hailong, et al.
Publicado: (2023)

Economic and Humanistic Burden of Triple-Negative Breast Cancer: A Systematic Literature Review
por: Huang, Min, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_islogrbrdbd2bljdssvqafol9b